PTO/SB/08B(07-05)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

for form 1449B/PTO Complete if Known THE COND SUPPLEMENTAL Application Number 09/707,576 Filing Date November 6, 2000 INFORMATION DISCLOSURE First Named Inventor Charles L. Magness STATEMENT BY APPLICANT Art Unit (Use as many sheets as necessary) Anna Skibinsky Examiner Name Attorney Docket Number 55382-3 Sheet of | 1

·		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials * No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-number(s), publisher, city and/or country where published.					
(iS)		FOWKE, K. R. et al., Resistance to HIV-1 Infection Among Persistently Seronegative Prostitutes in Nairobl., Kenya, <i>The Lancet 348</i> :1347-1351, 1996.			
		LIN, P. et al., NAD(P)H: Quinone Oxidoreductase Polymorphism and Lung Cancer in Taiwan, J. Toxicoloty and Environmental Health, Part A, 58187-197, 1999.			
	,				
_					
			l		
		·			
		•			

Examiner Signature Date Considered 5/4/07			
	Sing	l	5/4/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-



PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

tion Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Attorney Docket Number

SUPPLEMENTAL INFORMATION **DISCLOSURE STATEMENT BY APPLICANT** 

Complete if Known Application Number 09/707,576 Filing Date November 6, 2000 First Named Inventor Charles L. Magness 1631 Art Unit Examiner Name Anna Skibinsky

55382-3

(Use as many sheets as necessary) Sheet of

<del></del>		NON PATENT LITERATURE DOCUMENTS	1
Examiner Initials *	Cite No.1	Iriclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т;
al		LIN, P. et al., NAD(P)H: Quinone Oxidoreductase Polymorphism and Lung Cancer in Taiwan, Journal of Toxicology and Environmental health, Part A, 58:187-197, 1999.	
		DREWS, J., Genomic Sciences and the Medicine of Tomorrow, Nature Biotechnology 14:1516-1517, 1996.	
		BUIMOL, T. F. and WATANABE, A. M., Genetic Information, Genomic Technologies, and the Future of Drug Discovery, <i>JAMA 285</i> (5):551-555, 2001.	
		,	
	ļ		₩-

Examiner Signature	Q.	grish.	Date Considered	5/4/07
-----------------------	----	--------	--------------------	--------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450; Alexandria, VA 22313-1450.